On the recentest conference call, DRK showed her cards.
"My team and I have never been singularly focused on bringing just one drug to market. Instead, finding a way to shift the paradigm and create a platform that shortens the development time while producing multiple targeted therapies. In parallel and aligned to our strategy of bringing forth the best therapies to treat the widest array of patients with genetic diseases, we are pleased to announce the advancement of our MyoAAV platform with the Broad Institute of MIT and Harvard. MyoAAV is a new group of adeno-associated viruses that uses a modified capsid or outer protein shell of AAV to deliver genetic therapies with greater efficiency and at lower doses.
The platform has the potential to offer another breakthrough in genetic medicine delivery..."